Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine.

Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Schwarz AJ, Pendse G, Wallin D, Nutile L, Bishop J, George E, Elman I, Sunkaraneni S, Maier G, Iyengar S, Evelhoch JL, Bleakman D, Hargreaves R, Becerra L, Borsook D.

Neuroimage. 2012 Feb 15;59(4):3762-73. doi: 10.1016/j.neuroimage.2011.11.034. Epub 2011 Nov 18.

PMID:
22119647
3.

Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Huang P, Kehner GB, Cowan A, Liu-Chen LY.

J Pharmacol Exp Ther. 2001 May;297(2):688-95.

4.

Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model.

Koppert W, Ihmsen H, Körber N, Wehrfritz A, Sittl R, Schmelz M, Schüttler J.

Pain. 2005 Nov;118(1-2):15-22. Epub 2005 Sep 9.

PMID:
16154698
6.

Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.

Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, Wolfram G.

J Pain Symptom Manage. 2008 Aug;36(2):117-25. doi: 10.1016/j.jpainsymman.2007.09.011. Epub 2008 Apr 14.

PMID:
18411010
7.

Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.

Oifa S, Sydoruk T, White I, Ekstein MP, Marouani N, Chazan S, Skornick Y, Weinbroum AA.

Clin Ther. 2009 Mar;31(3):527-41. doi: 10.1016/j.clinthera.2009.03.018.

PMID:
19393843
9.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
10.

Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients.

Mercadante S, Ferrera P, Villari P.

Support Care Cancer. 2007 Apr;15(4):441-4. Epub 2006 Nov 15.

PMID:
17106658
11.

Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.

Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD.

J Anal Toxicol. 1996 Oct;20(6):369-78.

PMID:
8889672
12.

Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.

Kögel B, Christoph T, Strassburger W, Friderichs E.

Eur J Pain. 2005 Oct;9(5):599-611.

PMID:
16139189
13.

Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.

Koltzenburg M, Pokorny R, Gasser UE, Richarz U.

Pain. 2006 Dec 15;126(1-3):165-74. Epub 2006 Aug 9.

PMID:
16901645
15.

Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects.

Becerra L, Upadhyay J, Chang PC, Bishop J, Anderson J, Baumgartner R, Schwarz AJ, Coimbra A, Wallin D, Nutile L, George E, Maier G, Sunkaraneni S, Iyengar S, Evelhoch JL, Bleakman D, Hargreaves R, Borsook D.

J Pharmacol Exp Ther. 2013 Apr;345(1):41-51. doi: 10.1124/jpet.112.201145. Epub 2013 Jan 31.

16.

Imaging drugs with and without clinical analgesic efficacy.

Upadhyay J, Anderson J, Schwarz AJ, Coimbra A, Baumgartner R, Pendse G, George E, Nutile L, Wallin D, Bishop J, Neni S, Maier G, Iyengar S, Evelhoch JL, Bleakman D, Hargreaves R, Becerra L, Borsook D.

Neuropsychopharmacology. 2011 Dec;36(13):2659-73. doi: 10.1038/npp.2011.156. Epub 2011 Aug 17.

17.

Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.

Becker WC, Ganoczy D, Fiellin DA, Bohnert AS.

J Subst Abuse Treat. 2015 Jan;48(1):128-31. doi: 10.1016/j.jsat.2014.09.007. Epub 2014 Sep 26.

PMID:
25312475
18.

Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone.

Ling W, Hillhouse M, Jenkins J, Miotto K, Torrington M, Chapleo C.

J Addict Med. 2012 Jun;6(2):118-23. doi: 10.1097/ADM.0b013e31824fceca.

PMID:
22475985
19.

Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT.

Clin Pharmacokinet. 2004;43(5):329-40.

PMID:
15080765
20.

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Casuccio A.

J Pain Symptom Manage. 2006 Aug;32(2):175-9.

PMID:
16877185

Supplemental Content

Support Center